건일로딘 정(미결정에토돌락 200 ㎎)에 대한 에토돌 정의 생물학적동등성

이정애,이윤영,조태섭,박영준,문병석,김호현,이예리,이희주,이경률 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.4

A bioequivalence of Etodol™ tablets (Yuhan corporation) and Kuhnillodine™ tablets (Kuhnil Pharm, Co., Ltd.) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Single 200 ㎎ dose of etodolac of each medicine was administered orally to 24 healthy male volunteers. This study was performed in a 2×2 cross-over design. Concentrations of etodolac in human plasma were monitored by a high-performance liquid chromatography. AUCt (the area under the plasma concentration-time curve from time zero to 24 hr) was calculated by the linear trapezoidal rule method. C_(max) (maximum plasma drug concentration) and T_(max) (time to reach C_(max)) were compiled from the plasma concentration-time data. Analysis of variance was performed using logarithmically transformed AUCt and C_(max). No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the AUCt ratio and the C_(max) ratio for Etodol™/Kuhnillodine™ were 1.01 - 1.10 and 0.87 - 1.06, respectively. This study demonstrated a bioequivalence of Etodol™ and Kuhnillodine™ with respect to the rate and extent of absorption.

간호대학생이 지각하는 임상실습지도자의 교수효율성과 임상실습만족도의 관계

황현아,김희진,김예지,이규희,이영롱,박성희,손수빈 이화여자대학교 간호과학대학 2012 이화간호학회지 Vol.- No.46

Purpose: The purpose of this study was to investigate the relationship between teaching effectiveness and clinical practice satisfaction among nursing students. Method: The subjects of this study were 107 junior and senior nursing students in E university. Data were collected using self-reported questionnaire including general and practicum related characteristics, teaching effectiveness of clinical instructors and clinical practice satisfaction from September 12 to September 21, 2011. Collected data were analyzed by SPSS 19 program using t-test, ANOVA with Scheffe test, and Pearson`s correlation coefficients. Result: The mean score of teaching effectiveness was 3.35(±.51), and mean of clinical practice satisfaction was 3.19±.47. There were significant differences of teaching effectiveness of clinical instrutor by satisfaction of overall clinical practicum(F=8.332, p<.001), satisfaction of practice hour(F=3.230, p=.044), and satisfaction of major(F=9.883, p<.001). There were significant differences of clinical practice satisfaction by grade(t=2.274, p=.025), motive of choosing nursing science as a major(F=3.329, p=.007), satisfaction of overall clinical practicum(F=17.437, p<.001), satisfaction of practice hours(F=9.925, p<.001), and satisfaction of nursing major(F=12.748, p<.001). Relationship between teaching effectiveness of clinical instructor and clinical practice satisfaction showed positive correlation(r=.704, p<.001). Conclusion: In this study, teaching effectiveness of clinical instructor was related with clinical practice satisfaction. Therefore, we should consider improving teaching effectiveness of clinical instructor to improve clinical practice satisfaction.

루리드 정(록시스로마이신 150㎎)에 대한 록시스린 정의 생물학적동등성

정선경,이윤영,조태섭,김호현,이예리,이경률,이희주 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.3

A bioequivalence study of Roxithrin™ tablet (Kukje Pharma. Ind. Co., Ltd.) to Rulid™ tablet (Han Dok Pharma. Ind. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the roxithromycin dose of 300 mg in a 2×2 crossover study. There was a one-week wash-out period between the doses. Plasma concentrations of roxithromycin were monitored by a high-performance liquid chromatography for over a period of 36 hours after drug administration. AUC, (the area under the plasma concentration-time curve from time zero to 36 hr) was calculated by the linear trapezoidal rule method. C_(max) (maximum plasma drug concentration) and T_(max) (time to reach C_(max)) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed AUC, and C_(max). No significant sequence effect was found for all of the bioavailability parameters indicating that the cross-over design was properly performed. The 90% confidence intervals of the AUC, ratio and the C_(max) ratio for Roxithrin™/Rulid™ were 1.00 - 1.13 and 0.98 - 1.10, respectively. These values were within the acceptable bioequivalence intervals of 0.80 - 1.25. Thus, our study demonstrated the bioequivalence of Roxithrin™ and Rulid™ with respect to the rate and extent of absorption.

동아가스터 정(파모티딘 20㎎)에 대한 베스티딘 정의 생물학적동등성

박창훈,정선경,최미희,김호현,이예리,이희주,이경률 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.6

A bioequivalence study of Bestidine™ tablets (Choong Wae Pharma. Corp., Korea) to Dong-A Gaster™ (Dong-A Pharmaceutical Co.. Ltd.. Korea) tablets was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the famotidine dose of 40 mg in a 2x2 crossover study. There was a one-week wash out period between the doses. Plasma concentrations of famotidine were monitored by a high-performance liquid chromatography for over a period of 12 hours after the administration. AUCr (the area under the plasma concentration-time curve from time zero to 12 hr) was calculated by the linear trapezoidal rule method. Cma, (maximum plasma drug concentration) and Tma, (time to reach Cma,) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed AUCr and Cma,. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the AUCr ratio and the Cmax ratio for Bestidine™/ Gaster™ were log 0.90-log 1.06 and log 0.98-log 1.20. respectively. These values were within the acceptable bioequivalence intervals of 0.80-1.25. Thus, our study demonstrated the bioequivalence of Bestidine™ and Gaster™ with respect to the rate and extent of absorption.

담배 박각시나방 Manduca sexta의 계획된 세포죽음동안의 Proteasome의 변화

이구봉,우기민,조만희,이상한,장예진,김창세 순천향의학연구소 2000 Journal of Soonchunhyang Medical Science Vol.6 No.2

모든 진핵세포의 주요 단백질 분해요소인 proteasome은 변성되거나 상해된 불필요한 단백질을 제거할 뿐만 아니라, 세포주기를 비롯한 다양한 대사과정들의 주요 효소들을 필요 시 적절히 분해함으로써 항상성을 유지시키는 필수적인 효소로 잘 알려져 있다. 또한 proteasome은 특정 포유동물 조직의 계획된 세포죽음(programmed cell death 또는 apoptosis)와 밀접하게 관련되어 있다고 보고된 바, 본 연구에서는 담배 박각시나방(Manduca sexta)의 변태과정에서 일어나는 마디간 근육(intersegmental muscle)의 급격한 파괴과정동안의 proteasome의 변화양상을 발현 및 단백질 분해활성을 중점으로 조사하였다. 정상근육과 파괴직전의 근육으로부터 proteasome을 분석한 결과 단백질 분해활성이 최소한 6배 이상 증가하였으며, proteasome의 주요 구성성분들의 발현 변화를 각각의 항체(antibody)를 이용하여 조사한 결과 세포죽음 직전에 급격히 증가함을 보였다. 이러한 구성성분들의 발현증가가 proteasome 복합체 형성을 통해 활성의 증가를 일으키는지 조사한 결과, 세포내에서 실질적으로 단백질 분해활성을 담당한다고 여겨지는 26S proteasome(2,000 kDa)의 위치에서 커다란 활성의 변화와 구성성분의 증가를 볼 수 있었다. 따라서, 담배 박각시나방의 계획된 세포죽음 현상은 특정 호르몬의 신호에 의해 proteasome의 발현이 급격히 증가하여 26S proteasome의 복합체 형태로 세포 내 대부분의 단백질들을 분해함으로써 30시간이내 근육조직을 완전히 소멸시키는 것을 알 수 있었다. 한편, proteasome을 구성하는 특정 구성성분의 과다 발현이 세포의 단백질 분해현상에 어떠한 영향을 미치는 지 조사하기 위하여 쥐의 fibroblast cell에 26S proteasome의 ATPase 구성성분인 m56 유전자를 삽입한 후 세포의 추출물로부터 proteasome의 양과 활성의 변화를 관찰하였다. Proteasome을 초원심분리로 추출하여 관찰한 결과, 담배 박각시나방의 경우와는 달리 유전자 삽입 세포는 모든 실험에서 정상 세포와 전혀 차이를 보이지 않았다. 이 결과로부터 세포의 생명 유지에 필수적이고 매우 다양한 기능을 가진 proteasome은 40여개의 구성성분들의 발현이 매우 정교하게 조절되고 있으며, 특정 세포죽음 자극(apoptotic signal)이 왔을 때 일련의 구성 성분들의 발현과 26S proteasome 복합체 형성이 증가함으로써 그 기능을 수행하는 것을 알 수 있으며, 보다 자세한 연구는 비정상적 단백질 분해나 세포죽음을 동반하는 여러 질환들의 원인과 현상을 규명할 수 있으며, 또한 그 활성을 조절함으로써 궁극적인 치료의 방향도 제시 가능할 것으로 기대된다.

포사맥스 정(알렌드론산나트륨 70mg)에 대한 대웅 알렌드로네이트 정 70mg의 생물학적 동등성

이예리,정선경,양승권,최기호,신용철,전형규,강승우,이희주 한국약제학회 2006 Journal of Pharmaceutical Investigation Vol.36 No.2

인간의 혈장아포지단백 A-I에 특이성을 지닌 단일클론항체 A-I30의 light chain의 가변부위를 coding하는 cDNA의 클로님

이상한,우기민,조만희,장예진,김창세,김정경 순천향의학연구소 1997 Journal of Soonchunhyang Medical Science Vol.3 No.2

I prepared a monoclonal antibody (mAb) A-l30 to HDL apolipoprotein A-l with the ultimate goals of expressing the valuable immunodiagnostic single-chain Fv (scFv) in Escherichia coli. The binding specificity of mAb A-l30 was determined by Western blot analysis. From the hybridoma cell line secreting mAb A-l30, poly(A)+ RNA was prepared and used as a template for cDNA synthesis and cloning. The nucleotide sequence analyses revealed that the variable regions of the heavy and light chains were members of mouse heavy chain subgroup ⅡA and κ light chain subgroup Ⅱ, respectively. Comparison of the nucleotide sequences with mouse immunoglobulin genes listed in the GenBank data base showed that the cDNAs have not been previously reported.

β-Carotene 이 혈중 효소활성도에 미치는 영향

이상한,우기민,조만희,장예진,김창세,김현철 순천향의학연구소 1997 Journal of Soonchunhyang Medical Science Vol.3 No.2

This study was carried out in order to observe the effects of ethanol and β-carotene on the cholesterol, Triglyceride, LDL-cholesterol, HDL-cholesterol, glutathione peroxidase and catalase activities. The normal white S.D rats were classified into 4 group: 0.9% NaCl administration and 20% ethanol administration were referred to as group A, 20% ethanol and 50% β-carotene mixture administration was group B and 50% β-carotene administration was group C for the 30 day-feeding experiment. The results were obtained as following: 1. The blood lipid concentration was most highly increased in group A, was almost normal in group B, but significantly decreased in goup C. 2. The blood antioxidant enzyme activities were significantly decreased in group A, but significantly increased in goup B and C. 3. The blood β-carotene concentration were significantly decreased in group A, and slightly decreased in group B. Surprisingly it was increased in group C.

모빅 캡슐(멜록시캄 7.5㎎)에 대한 멜락스 캡슐의 생물학적동등성

이예리,염승복,고연정,고정길,김호현,이희주,이경률 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.5

A bioequivalence of Melax capsules (Chong Kun Dang Pharm., Korea) and Mobic™ capsules (Boehringer Ingelheim Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Single 15 mg dose of meloxicam of each medicine was administered orally to 24 healthy male volunteers. This study was performed in a 2 x 2 crossover design. Concentrations of meloxicam in human plasma were monitored by a high-performance liquid chromatography. AUC, (the area under the plasma concentration-time curve from time zero to 72 hr) was calculated by the linear trapezoidal rule method. C_(max) (maximum plasma drug concentration) and T_(max) (time to reach Cma,.) were compiled from the plasma concentration-time data. Analysis of variance was performed using logarithmically transformed AUC, and C_(max). No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the AUCt ratio and the C_(max) ratio for Melax™/Mobic™ were 0.95 - 1.04 and 0.98 - 1.14, respectively. This study demonstrated a bioequivalence of Melax™ and Mobic™ with respect to the rate and extent of absorption.

사람의 혈장 아포지단백질 A-I에 대한 단일클론항체 A-I4-18의 생성 및 특성 분석

장예진,이상한,김동연,조만희,우기민 순천향의학연구소 1998 Journal of Soonchunhyang Medical Science Vol.4 No.1

본 연구는 사람의 고밀도 지단백질을 구성하는 아포지단백질 A-I에 특이적인 single-chain Fv를 클로닝하여 대장균 세포에서 발현시킬 목적으로, 먼저 단일클론항체 A-I4-18을 제조하였으며 이항체의 특성을 분석하였다. 아포지단백질 A-I을 BALB/c 생쥐에 면역한후 얻어진 비장세포를 Sp2/O myeloma세포주와 융합한 후 융합세포를 생쥐의 복강내에 주입하였으며, 복수를 채취하여 protein A Sepharose CL-4B크로마토그래피법으로 단일클론항체를 분리하였다. Isotyping결과 heavy chain은 subgroup IIa이며 κ형의 light chain을 나타내었으며 항원과의 결합특이성은 ELISA와 Western blotting법으로 확인하였다. Indirect ELISA법으로 얻어진 해리상수 (Kd)값은 8.33x10의 마이너스8승이었다.